Article Text
Statistics from Altmetric.com
Idiopathic pulmonary fibrosis (IPF) has no effective treatment and a relatively short life expectancy after diagnosis. Interferon α (IFNα) inhibits the growth of proliferating fibroblasts.1 IFNα also inhibits the production of collagen by fibroblasts independently of its effect on fibroblast replication.2 Biological activity of low-dose IFNα by oromucosal administration has been reported in several species including man,3 despite the expected rapid inactivation by digestive enzymes.4
We therefore tested the effect of oral administration of very low doses of IFNα on the progression of IPF. Twelve of 20 patients with IPF aged 50–82 years (mean 67) completed treatment for at least 12 months with IFNα administered by lozenge (150 IU) taken three times each day. IPF was diagnosed according to the diagnostic criteria set forth by the American Thoracic Society. Three subjects had …